Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.9% during the 4th quarter, Holdings Channel reports. The firm owned 359,706 shares of the biopharmaceutical company’s stock after selling 62,986 shares during the quarter. Russell Investments Group Ltd.’s holdings in Halozyme Therapeutics were worth $13,295,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HALO. Allspring Global Investments Holdings LLC lifted its stake in Halozyme Therapeutics by 174.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after buying an additional 563,989 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $15,280,000. Federated Hermes Inc. boosted its stake in shares of Halozyme Therapeutics by 176.0% in the fourth quarter. Federated Hermes Inc. now owns 459,369 shares of the biopharmaceutical company’s stock worth $16,978,000 after acquiring an additional 292,926 shares during the last quarter. Artisan Partners Limited Partnership increased its position in shares of Halozyme Therapeutics by 3.4% during the third quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock worth $294,632,000 after purchasing an additional 253,363 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in Halozyme Therapeutics by 930.9% in the 4th quarter. Handelsbanken Fonder AB now owns 246,069 shares of the biopharmaceutical company’s stock valued at $9,095,000 after purchasing an additional 222,200 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.2 %

Shares of NASDAQ:HALO opened at $39.91 on Friday. The firm has a market capitalization of $5.07 billion, a PE ratio of 18.91, a price-to-earnings-growth ratio of 0.46 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The firm’s 50-day moving average is $39.99 and its two-hundred day moving average is $37.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Analysts predict that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current year.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 30,000 shares of company stock worth $1,196,800. Corporate insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of research reports. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 30th. The Goldman Sachs Group dropped their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, January 18th. TD Cowen initiated coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective on the stock. Finally, TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.